According to the Summary of Product Characteristics (SmPC) approved by the MHRA, nausea is very common (may affect more than 1 in 10 people), whilst vomiting, diarrhoea, abdominal pain, and constipation are common (may affect up to 1 in 10 people)
They were able to contact 16 of the 17 patients to assess their outcomes, with most having received their injection 6 months to 1 year before the follow-up survey
Its not a magic bullet, but a tool to support your overall weight loss journey
Animal Data Liraglutide has been shown to be teratogenic in rats at or above 0.8-times systemic exposures in obese humans resulting from the maximum recommended human dose (MRHD) of 3 mg/day based on plasma area under the time-concentration curve (AUC) comparison
Clinicians often suggest this instead of risking the medication becoming less effective
Glutathione stays inside the mitochondria to clean up these byproducts